Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?

Valentina Svicher, Giulia Carla Marchetti, Adrianna Ammassari, Francesca Ceccherini-Silberstein, Loredana Sarmati, Massimo Andreoni, Gioacchino Angarano, Andrea Antinori, Guido Antonelli, Alessandra Bandera, Paolo Bonfanti, Stefano Bonora, Marco Borderi, Andrea Calcagno, Maria Rosaria Capobianchi, Antonella Castagna, Francesco Castelli, Roberto Cauda, Benedetto Maurizio Celesia, Antonio ChirianniStefania Cicalini, Antonella Cingolani, Paola Cinque, Massimo Clementi, Andrea Cossarizza, Antonella D’Arminio Monforte, Gabriella D’Ettorre, Andrea De Luca, Antonio Di Biagio, Giovanni Di Perri, Massimo Galli, Nicola Gianotti, Enrico Girardi, Giovanni Guaraldi, Adriano Lazzarin, Miriam Lichtner, Sergio Lo Caputo, Giordano Madeddu, Paolo Maggi, Franco Maggiolo, Giulia Carla Marchetti, Claudio Mastroianni, Cristina Mussini, Silvia Nozza, Giuseppe Nunnari, Saverio Parisi, Giustino Parruti, Carlo Federico Perno, Maria Santoro, Mauro Zaccarelli, Impact Study Group

Research output: Contribution to journalArticle

Abstract

The high potency and tolerability of the currently available antiretroviral drugs has modified HIV-1 infection from a life-threatening disease to a chronic illness. Nevertheless, some issues still remain open to optimize the management of HIV-1 infected patients in term of maintenance of virological suppression over time, identifying patients that could benefit from simplification therapy, and reducing co-mordibities driven by chronic inflammation. The availability of robust and affordable virological and immunological markers can help in solving these issues by providing information on the burden of HIV-1 reservoir in all the anatomical compartments in which the virus replicates as well as on persistent inflammation, immune activation and senescence despite successful virological suppression. In this light, this review is aimed at providing new insights (arising from a two-day Italian expert meeting hold in Rome in March 2016) in evaluation and monitoring of HIV-1 infection from a virological, immunological and clinical perspective. Particular attention has been focused on role of novel parameters (such as total HIV-1 DNA, residual viremia, and immunological markers) in optimizing treatment strategies, enhancing medical adherence, and individualizing monitoring.

Original languageEnglish
Pages (from-to)119-133
Number of pages15
JournalAIDS Reviews
Volume19
Issue number3
DOIs
Publication statusPublished - Jul 1 2017

    Fingerprint

Keywords

  • Genotypic resistance testing
  • HIV-DNA
  • Immune-activation
  • Inflammation
  • Low level viremia
  • Residual viremia

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Svicher, V., Marchetti, G. C., Ammassari, A., Ceccherini-Silberstein, F., Sarmati, L., Andreoni, M., Angarano, G., Antinori, A., Antonelli, G., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Capobianchi, M. R., Castagna, A., Castelli, F., Cauda, R., Celesia, B. M., ... Impact Study Group (2017). Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? AIDS Reviews, 19(3), 119-133. https://doi.org/10.24875/AIDSRev.M17000003